Vident Advisory LLC Acquires New Stake in Hims & Hers Health, Inc. $HIMS

Key Points

• Vident Advisory LLC has acquired a new position in Hims & Hers Health, purchasing 27,889 shares worth approximately $824,000 in the first quarter.
• Hims & Hers Health reported a 72.6% increase in revenue year-over-year for the last quarter but fell short of earnings expectations with $0.17 EPS compared to the estimated $0.18.
• Insider transactions showed significant sales, with a total of 1,390,328 shares sold by insiders in the last 90 days, representing a combined value of $71,468,298.

Vident Advisory LLC purchased a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 27,889 shares of the company's stock, valued at approximately $824,000.

Several other institutional investors have also recently added to or reduced their stakes in HIMS. Farallon Capital Management LLC lifted its position in shares of Hims & Hers Health by 64,338.5% during the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock worth $202,556,000 after purchasing an additional 8,364,000 shares during the last quarter. Nuveen LLC bought a new position in shares of Hims & Hers Health during the first quarter worth about $58,403,000. Yong Rong HK Asset Management Ltd lifted its position in shares of Hims & Hers Health by 41.2% during the first quarter. Yong Rong HK Asset Management Ltd now owns 2,400,000 shares of the company's stock worth $70,920,000 after purchasing an additional 700,100 shares during the last quarter. CloudAlpha Capital Management Limited Hong Kong bought a new position in shares of Hims & Hers Health during the first quarter worth about $20,580,000. Finally, Jump Financial LLC lifted its position in shares of Hims & Hers Health by 633.2% during the first quarter. Jump Financial LLC now owns 725,445 shares of the company's stock worth $21,437,000 after purchasing an additional 626,496 shares during the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Hims & Hers Health news, CEO Andrew Dudum sold 128,127 shares of the firm's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $45.06, for a total value of $5,773,402.62. Following the sale, the chief executive officer owned 89,521 shares in the company, valued at approximately $4,033,816.26. This trade represents a 58.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Michael Chi sold 2,100 shares of the firm's stock in a transaction that occurred on Thursday, July 24th. The shares were sold at an average price of $57.52, for a total transaction of $120,792.00. Following the completion of the sale, the insider owned 278,654 shares in the company, valued at $16,028,178.08. The trade was a 0.75% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,390,328 shares of company stock valued at $71,468,298 in the last ninety days. Insiders own 13.71% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on HIMS. Truist Financial reduced their price target on shares of Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating on the stock in a research report on Monday, August 18th. UBS Group set a $30.00 price target on shares of Hims & Hers Health in a research report on Monday, June 23rd. Needham & Company LLC reaffirmed a "hold" rating on shares of Hims & Hers Health in a research report on Tuesday, August 5th. Morgan Stanley reaffirmed an "equal weight" rating and set a $40.00 price target on shares of Hims & Hers Health in a research report on Wednesday, June 11th. Finally, Citigroup reiterated a "sell" rating on shares of Hims & Hers Health in a research note on Monday, June 23rd. Two equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Reduce" and an average target price of $38.92.

Hims & Hers Health Stock Performance

Shares of Hims & Hers Health stock traded up $0.28 during trading on Friday, hitting $48.39. 24,006,280 shares of the stock were exchanged, compared to its average volume of 22,830,452. The stock's fifty day moving average is $50.03 and its 200 day moving average is $45.41. The stock has a market cap of $10.94 billion, a PE ratio of 60.49, a P/E/G ratio of 3.25 and a beta of 2.14. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98. Hims & Hers Health, Inc. has a 12 month low of $13.47 and a 12 month high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The firm had revenue of $544.83 million for the quarter, compared to the consensus estimate of $550.06 million. During the same quarter in the prior year, the company posted $0.06 EPS. The firm's revenue was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.